FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients
NCT ID: NCT02704468
Last Updated: 2016-07-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
100 participants
Study Classification
OBSERVATIONAL
Study Start Date
2016-01-31
Study Completion Date
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Chronic kidney disease(CKD) patients have high incidence of coronary artery problems event after renal transplantation. And remain a major cause of mortality. The major risk marker is arterial stiffness. The cardio-ankle vascular index (CAVI) is a new index of overall stiffness and can estimated the risk of atherosclerosis.
Fibroblast growth factor 21 (FGF-21) is a metabolic regulator that plays important role in cardiac remodeling elevated FGF-21 have been reported in coronary heart disease or carotid artery plaque and could be biomarkers for atherosclerosis disease Investigators aimed to study the association between CAVI and FGF-21 and their relations to various parameters that can contribute to cardiovascular disease eg. homocysteine Echocardiogram findings and other traditional basic factors.
Fibroblast growth factor 21 (FGF-21) is a metabolic regulator that plays important role in cardiac remodeling elevated FGF-21 have been reported in coronary heart disease or carotid artery plaque and could be biomarkers for atherosclerosis disease Investigators aimed to study the association between CAVI and FGF-21 and their relations to various parameters that can contribute to cardiovascular disease eg. homocysteine Echocardiogram findings and other traditional basic factors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Arterial Stiffness and AKI Post-CABG
NCT02364427
Acute Kidney Injury
COMPLETED
Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients
NCT01154842
Fibroblast
UNKNOWN
Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury
NCT02165072
Acute Kidney Injury
COMPLETED
Application of Intraoperative Transesophageal Echocardiography Imaging of Vein and CLCVP in Early Prediction and Intervention CSA-AKI
NCT05682716
Acute Kidney Injury
COMPLETED
NA
Prevention and Early Detection and Intervention of Post-Coronary Artery Bypass Grafting Surgery (CABG) Acute Kidney Injury (AKI)
NCT02838667
Acute Renal Injury
Preventive Measures
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 90 participants who underwent renal transplant were included in the study. The following measures were done and laboratory data were collected. CAVI, Ecchocariogram, Homocysteine, Hs-CRP, Carotid IMT, FGF-21, Medication after renal transplantation, incidence of cardiovascular disease correlation between categorical data was done by using Pearson's correlation test and multiple regression analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Vascular Stiffness
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CAVI and FGF-21
renal transplant patients for more than 1 month measured FGF-21 and CAVI
CAVI and FGF-21
Intervention Type
OTHER
FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAVI and FGF-21
FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* renal transplant patients patients for more than 1 month
Exclusion Criteria
* who had contraindication for CAVI
* current smoker
* eGFR \<15 ml/min/173
* cardiac arrthymia
* current smoker
* eGFR \<15 ml/min/173
* cardiac arrthymia
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bangkok Metropolitan Administration Medical College and Vajira Hospital
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thananda Trakarnvanich
Associated Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thananda Trakarnvanich, M.D.
Role: STUDY_DIRECTOR
Bangkok metropolitan administration medical college of vajira hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bangkok metropolitan administraiton of vajira hospital
Bangkok, Bangkok, Thailand
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Thailand
References
Explore related publications, articles, or registry entries linked to this study.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003 Oct 28;108(17):2154-69. doi: 10.1161/01.CIR.0000095676.90936.80. No abstract available.
Reference Type
BACKGROUND
An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ, Kim DJ, Lee KW. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract. 2012 May;96(2):196-203. doi: 10.1016/j.diabres.2012.01.004. Epub 2012 Jan 30.
Reference Type
BACKGROUND
Verbeke F, Marechal C, Van Laecke S, Van Biesen W, Devuyst O, Van Bortel LM, Jadoul M, Vanholder R. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension. 2011 Nov;58(5):833-8. doi: 10.1161/HYPERTENSIONAHA.111.176594. Epub 2011 Sep 6.
Reference Type
BACKGROUND
Khoshdel AR, Carney SL. Arterial stiffness in kidney transplant recipients: an overview of methodology and applications. Urol J. 2008 Winter;5(1):3-14.
Reference Type
BACKGROUND
Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia. 2008 Apr;51(4):527-39. doi: 10.1007/s00125-007-0918-3. Epub 2008 Feb 1.
Reference Type
BACKGROUND
Sun CK. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. Integr Blood Press Control. 2013 Apr 30;6:27-38. doi: 10.2147/IBPC.S34423. Print 2013.
Reference Type
BACKGROUND
Kim KJ, Lee BW, Kim HM, Shin JY, Kang ES, Cha BS, Lee EJ, Lim SK, Lee HC. Associations between cardio-ankle vascular index and microvascular complications in type 2 diabetes mellitus patients. J Atheroscler Thromb. 2011;18(4):328-36. doi: 10.5551/jat.5983. Epub 2011 Jan 6.
Reference Type
BACKGROUND
Takaki A, Ogawa H, Wakeyama T, Iwami T, Kimura M, Hadano Y, Matsuda S, Miyazaki Y, Matsuda T, Hiratsuka A, Matsuzaki M. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J. 2007 Nov;71(11):1710-4. doi: 10.1253/circj.71.1710.
Reference Type
BACKGROUND
Hayashi K, Sato M, Niimi H, Handa H, Moritake K. [Analysis of the constitutive laws of the vascular wall by finite deformation theory]. Iyodenshi To Seitai Kogaku. 1975 Oct;13(5):293-8. No abstract available. Japanese.
Reference Type
BACKGROUND
KOTANI, K.; REMALEY, A. T. Cardio-AnkleVascular Index (CAVI) and its Potential Clinical Implications for Cardiovascular Disease. CardiolPharmacol, 2013, 2: 108.
Reference Type
BACKGROUND
Otsuka K, Fukuda S, Shimada K, Suzuki K, Nakanishi K, Yoshiyama M, Yoshikawa J. Serial assessment of arterial stiffness by cardio-ankle vascular index for prediction of future cardiovascular events in patients with coronary artery disease. Hypertens Res. 2014 Nov;37(11):1014-20. doi: 10.1038/hr.2014.116. Epub 2014 Jul 10.
Reference Type
BACKGROUND
Dobsak P, Soska V, Sochor O, Jarkovsky J, Novakova M, Homolka M, Soucek M, Palanova P, Lopez-Jimenez F, Shirai K. Increased cardio-ankle vascular index in hyperlipidemic patients without diabetes or hypertension. J Atheroscler Thromb. 2015;22(3):272-83. doi: 10.5551/jat.24851. Epub 2014 Oct 22.
Reference Type
BACKGROUND
Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, Miyashita Y, Saiki A, Takahashi M, Suzuki K, Takata M. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011;18(11):924-38. doi: 10.5551/jat.7716. Epub 2011 May 31.
Reference Type
BACKGROUND
Cheng HM, Chuang SY, Sung SH, Yu WC, Pearson A, Lakatta EG, Pan WH, Chen CH. Derivation and validation of diagnostic thresholds for central blood pressure measurements based on long-term cardiovascular risks. J Am Coll Cardiol. 2013 Nov 5;62(19):1780-7. doi: 10.1016/j.jacc.2013.06.029. Epub 2013 Jul 10.
Reference Type
BACKGROUND
Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D, Logvinova A, Ross CA, Greenberg DA, Ellerby LM. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18189-94. doi: 10.1073/pnas.0506375102. Epub 2005 Dec 2.
Reference Type
BACKGROUND
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005 Jun;115(6):1627-35. doi: 10.1172/JCI23606. Epub 2005 May 2.
Reference Type
BACKGROUND
Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008 Dec;149(12):6018-27. doi: 10.1210/en.2008-0816. Epub 2008 Aug 7.
Reference Type
BACKGROUND
Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007 Feb;148(2):774-81. doi: 10.1210/en.2006-1168. Epub 2006 Oct 26.
Reference Type
BACKGROUND
Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Mar;58(3):464-73. doi: 10.1007/s00125-014-3458-7. Epub 2014 Nov 26.
Reference Type
BACKGROUND
Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2010 Dec 29;5(12):e15534. doi: 10.1371/journal.pone.0015534.
Reference Type
BACKGROUND
Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L, Larsson TE. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009 Oct;24(10):3125-31. doi: 10.1093/ndt/gfp205. Epub 2009 May 9.
Reference Type
BACKGROUND
Lee Y, Lim S, Hong ES, Kim JH, Moon MK, Chun EJ, Choi SI, Kim YB, Park YJ, Park KS, Jang HC, Choi SH. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf). 2014 Jan;80(1):57-64. doi: 10.1111/cen.12134. Epub 2013 May 6.
Reference Type
BACKGROUND
Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O'Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009 Apr;30(7):850-6. doi: 10.1093/eurheartj/ehn573. Epub 2009 Jan 9.
Reference Type
BACKGROUND
Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, Tse HF, Chau MT, Cheung BM, Lam KS. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2454-9. doi: 10.1161/ATVBAHA.113.301599. Epub 2013 Jul 25.
Reference Type
BACKGROUND
Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens. 2013 Jun;27(6):397-9. doi: 10.1038/jhh.2012.52. Epub 2012 Nov 29.
Reference Type
BACKGROUND
Chen YC, Lee MC, Lee CJ, Ho GJ, Yin WY, Chang YJ, Hsu BG. N-terminal pro-B-type natriuretic peptide is associated with arterial stiffness measured using the cardio-ankle vascular index in renal transplant recipients. J Atheroscler Thromb. 2013;20(7):646-53. doi: 10.5551/jat.17780. Epub 2013 May 10.
Reference Type
BACKGROUND
Deo R, Shou H, Soliman EZ, Yang W, Arkin JM, Zhang X, Townsend RR, Go AS, Shlipak MG, Feldman HI. Electrocardiographic Measures and Prediction of Cardiovascular and Noncardiovascular Death in CKD. J Am Soc Nephrol. 2016 Feb;27(2):559-69. doi: 10.1681/ASN.2014101045. Epub 2015 Jul 9.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
085/58
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Application of CLCVP Technique in Early Intervention of CSA-AKI
NCT05855954
RECRUITING
NA
A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine
NCT06772025
RECRUITING
NA
Association Between Renal Resistive Index(RRI) and AKI(Acute Kidney Injury) in Cardiac Surgery Patients With Cardiopulmonary Bypass (CPB)
NCT06464666
NOT_YET_RECRUITING
Carotid Doppler and IVC Measurements for Volume Guided Management in Acute Kidney Injury Patients
NCT05938049
NOT_YET_RECRUITING
AVF Volume Blood Flow Reduction in HD Patients
NCT06807138
COMPLETED
FGF23 as a Marker of Acute Kidney Injury
NCT04693962
UNKNOWN
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
NCT02325726
COMPLETED
Inferior Vena Cava Collapsibility Index and Intradialytic Hypotension
NCT07033273
RECRUITING
Predictive Tools for the Presence of Significant Coronary Artery Disease Requiring Intervention in Chronic Hemodialysis Patients
NCT06661941
COMPLETED
Nephrologic Intervention in Patients Waiting for Cardiac Surgery
NCT02643745
COMPLETED
NA
Vascular Calcification's Risk Factors in Haemodialysis Patients
NCT00694824
COMPLETED
Cardiovascular Surgery Early Prediction System for AKI :CARDS-AKI Registry
NCT07330453
NOT_YET_RECRUITING
Early RRT in AKI After Cardiac Surgery
NCT05175053
RECRUITING
NA
Preoperative RRI and Long-term Risk for CKD
NCT05577039
COMPLETED
Microalbuminuria Predicting CIAKI After CAG
NCT02808845
UNKNOWN
Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty
NCT02642731
COMPLETED
Predicting Acute Kidney Injury After Coronary Artery Bypass Graft
NCT02081261
COMPLETED
Renal Physiology During Continuous Renal Replacement Therapy
NCT04114747
RECRUITING
NA
Biomarker-guided Intervention to Prevent Acute Kidney Injury
NCT04647396
COMPLETED
NA
Machine Learning Predict Renal Replacement Therapy After Cardiac Surgery
NCT04977687
COMPLETED
Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure
NCT02259296
UNKNOWN
NA
Evaluation of Endothelial Dysfunction Using the "Flow Mediated Dilation" Test in a Population of Chronic Renal Failure Patients at Different Stages, and Evaluation of the Role of Antiphospholipid Antibodies
NCT06347029
RECRUITING
NA
The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
NCT05214872
COMPLETED
AKI Prevention and Early Intervention in Patients Undergoing VAD Placement
NCT03236831
COMPLETED
NA